Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,170 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.09, for a total value of $58,785.30. Following the completion of the sale, the insider owned 51,384 shares of the company’s stock, valued at approximately $1,391,992.56. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, July 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.30, for a total transaction of $65,781.30.
• On Wednesday, June 17th, David Malcom Rodman sold 4,584 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $114,600.00.
• On Monday, June 15th, David Malcom Rodman sold 9,890 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $23.81, for a total value of $235,480.90.
• On Friday, June 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $23.93, for a total value of $151,931.57.
• On Wednesday, June 10th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $54,250.00.
• On Monday, May 18th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.55, for a total value of $11,488.35.

Mineralys Therapeutics Price Performance

Shares of NASDAQ:MLYS traded down $0.28 during trading on Wednesday, reaching $27.05. 1,396,596 shares of the stock were exchanged, compared to its average volume of 628,579. Mineralys Therapeutics, Inc. has a 1-year low of $12.59 and a 1-year high of $47.65. The stock has a fifty day moving average of $26.42 and a two-hundred day moving average of $27.60.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). Sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MLYS has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Wall Street Zen downgraded Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen started coverage on Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Mineralys Therapeutics News Summary

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Regulatory milestone remains on track: The company reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational treatment for hypertension, and said commercial launch preparations are progressing in anticipation of approval. Mineralys second-quarter results and corporate update
• Positive Sentiment: Financial flexibility improved: Management highlighted a strong cash position with funding expected to support operations into 2028. Strategic financing initiatives and the repurchase of the Tanabe royalty obligation also strengthen the long-term economics of lorundrostat by reducing a future royalty burden. Mineralys launch readiness and cash runway
• Positive Sentiment: New medical leadership: Mineralys appointed cardiovascular medicine executive Dr. Terry Ferguson as chief medical officer. He will oversee medical strategy and late-stage clinical activities ahead of the potential lorundrostat launch. Mineralys appoints chief medical officer
• Neutral Sentiment: Short-interest data offered little signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio, suggesting the data does not indicate meaningful short-selling pressure.
• Negative Sentiment: Quarterly loss missed expectations sharply: Mineralys reported a second-quarter loss of $2.85 per share, compared with the analyst consensus estimate of a $0.55 loss. The sizable variance may be weighing on the stock, although the company remains focused on its pre-commercial development and launch activities. Mineralys second-quarter earnings call transcript

Institutional Trading of Mineralys Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new stake in Mineralys Therapeutics in the 1st quarter valued at about $550,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Mineralys Therapeutics by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock worth $271,000 after purchasing an additional 702 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Mineralys Therapeutics by 166.6% in the first quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after purchasing an additional 186,480 shares in the last quarter. Woodline Partners LP bought a new stake in shares of Mineralys Therapeutics in the first quarter valued at approximately $757,000. Finally, Creative Planning purchased a new stake in shares of Mineralys Therapeutics during the 2nd quarter valued at approximately $336,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.